Accreditation Information

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 10.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education Provider Unit Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Contact Hours: 10.17, of which up to 6.83 are eligible for pharmacology credit.

According to the criteria of the American Board of Certification for Gastroenterology Nurses (ABCGN), 8.66 hour(s) earned in this activity are considered GI Specific for the purpose of recertification by contact hours through the ABCGN.”

ABCGN tracking number: GI2017-073

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 10.75 hours of Category I credit for completing this program.


Needs Statement

An estimated 1.6 million individuals currently have IBD in the United States (US). A 2004 National Institute of Health (NIH) report revealed that there were 1.1 million ambulatory care visits for CD, 1.8 million prescriptions, and 187,000 hospitalizations specifically for CD annually. There were 716,000 ambulatory care visits and 2.1 million prescriptions for UC treatment, and 107,000 hospitalizations for patients with UC in 2010. The total annual financial burden of IBD in the US is estimated to be $14.6 billion to $31.6 billion when direct and indirect costs are taken into consideration.

Though advances have been made in the treatment of this disease, many patients do not achieve remission. As research reveals more insight into the pathophysiology of IBD, novel therapeutic targets are being identified that lead to the development of new therapeutic agents. These unique treatment options will give patients who have not been able to achieve treatment goals more options and a greater chance for success. As more information becomes available about IBD, gastroenterologists and other clinicians who manage/treat IBD must be knowledgeable and fully prepared to use this information in their practice and employ new agents as they become available so that all patients with IBD receive the best possible individualized care.



The goal of the activity is to initiate practice changes in GI practices in the diagnosis and management of patients with CD and UC so as to improve quality of life for these patients while prolonging clinical remission. This meeting will provide support and enable participating clinicians to enhance their knowledge, competency and performance in the areas of patient care, medical knowledge, and practice-based learning and improvement.
At the end of this conference, participants will be able to:

  • Determine the risks and benefits of newer biologic treatments in resistant cases of inflammatory bowel disease.
  • Evaluate the role of complementary therapies, including curcumin, probiotics, and dietary modifications in patients with inflammatory bowel disease.
  • Manage challenging extraintestinal manifestations of IBD including orofacial granulomatosis and eye inflammation.
  • Identify the most current approaches to the diagnosis of Crohn’s disease and ulcerative colitis.
  • Describe the best approaches for medical therapy of Crohn’s disease and ulcerative colitis.
  • Recognize the side effects and risks of using immunomodulatory and biologics in the treatment of Crohn’s disease and ulcerative colitis.
  • List the indications and type of surgeries for Crohn’s disease and ulcerative colitis.


Target Audience

This course is designed for practicing gastroenterologists, pediatric gastroenterologists, colorectal surgeons, nurses and other healthcare professionals caring for patients with Crohn’s disease (CD) and ulcerative colitis (UC).


Faculty Disclosure

Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.